Garrett Rhyasen serves as the Vice President of Search, Evaluation & Transactions at GSK. In this role, Garrett and his team oversee the identification, evaluation, negotiation, and execution of partnering opportunities that enhance GSK’s portfolio. Since assuming this position in 2022, Garrett has spearheaded notable transactions including licensing agreements with Wuxi, Hanosh, and Janssen, as well as the successful acquisition of Aiolos Bio.
Prior to GSK, Garrett held the position of Executive Director of and Head of Oncology Search & Evaluation and Transactions at AstraZeneca. Throughout his tenure, Garrett played a pivotal role in establishing numerous discovery partnerships, clinical collaborations, acquisitions, and licensing agreements. Notably, he led the investment case for the $6Bn datopotamab deruxtecan co-development/co-promotion deal with Daiichi Sankyo.
Before his time at AstraZeneca, Garrett held business development roles at Bristol Myers Squibb and Curis, Inc. He holds a BSc from the University of Victoria, a PhD in Cancer Biology from the University of Cincinnati and completed Postdoctoral research at AstraZeneca. Garrett is also credited an inventor on several patents and author of 11 peer-reviewed publications in the field of cancer biology.
